ResMed Inc. (RMD) - Breathe easy
November 5, 2024
ResMed Inc. develops, manufactures, distributes, and markets medical device and cloud-based software applications targeting the management of sleep apnoea. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service.
The company delivered a strong September quarter result, with 11% revenue growth translating to 35% earnings per share growth. Revenues were 3% ahead of consensus due to higher rates of flow generator growth.
The gross margin of 59.2% aligned with expectations, while operating expenses were slightly ahead of forecasts.
Net operating cash flow increased by 14% compared to the previous corresponding period, despite higher inventory due to rebalancing sea versus air freight. Net debt fell, while the value of share buyback program was boosted.
ResMed upped it FY25 EPS guidance thanks to jump higher flow generator revenues. Revenue growth for the current quarter is forecast at 10%. We forecast the company will be able to generate annualised EPS growth of 13% for the next few years, which justifies its current trading multiples. We ticked our price target up from $39.25 to $40.05 following the quarterly.
Insights that count
Discover the best opportunities to outperform the market. Our research team dig deep into the market, company and stock data to bring you insights others might overlook.
Sonic Healthcare (SHL) – German future fee focus
Sonic Healthcare offers medical diagnostic and administrative services to medical practitioners, hospitals, community health services, and patients in Australia, the US, Germany and elsewhere.
Collins Foods (CKF) – German expansion
Collins Foods operates KFC stores in Australia and Europe.
MA Financial Group (MAF) – Growth engine
MA Financial Group provides various financial services in Australia and operates through asset management, lending and technology, corporate advisory and equities divisions.
.jpg)